CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Biomarin Enters Into Exclusive Worldwide License Agreement With Gc Biopharma And Hanmi Pharm For Investigational Next-Generation Enzyme Replacement Therapy

By Reuters News

Oct 29 (Reuters) - BioMarin Pharmaceutical Inc. BMRN.O:

  • BIOMARIN ENTERS INTO EXCLUSIVE WORLDWIDE LICENSE AGREEMENT WITH GC BIOPHARMA AND HANMI PHARM FOR INVESTIGATIONAL NEXT-GENERATION ENZYME REPLACEMENT THERAPY, ADDING A SECOND POTENTIAL TREATMENT FOR FABRY DISEASE

  • BIOMARIN PHARMACEUTICAL - TO MAKE $70 MILLION UPFRONT PAYMENT; GC AND HANMI ELIGIBLE FOR MILESTONES AND ROYALTIES

  • BIOMARIN PHARMACEUTICAL - GC AND HANMI ELIGIBLE FOR UP TO $405 MILLION IN MILESTONE PAYMENTS AND ROYALTIES

  • BIOMARIN PHARMACEUTICAL - TO ASSUME SOLE RESPONSIBILITY FOR HM15421/GC1134A OUTSIDE KOREA

  • BIOMARIN PHARMACEUTICAL - GC AND HANMI RETAIN COMMERCIALIZATION RIGHTS FOR HM15421/GC1134A IN KOREA

Further company coverage: BMRN.O

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk